AI assistant
Sending…
Marker Therapeutics, Inc. — Director's Dealing 2004
Sep 15, 2004
35150_dirs_2004-09-15_78830e36-4300-4bf2-bbe6-ef7b1ae04378.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 3 — Initial Statement of Beneficial Ownership
Issuer: GENEMAX CORP (GMXX)
CIK: 0001094038
Period of Report: 2004-08-30
Reporting Person: Konstantine Sarafis (Chief Operating Officer)
Holdings (Derivative)
| Security | Exercise Price | Expiration | Underlying | Shares | Ownership |
|---|---|---|---|---|---|
| Common Stock Options | $0.50 | 2009-08-30 | Common Stock Options (100000) | Direct |
More from Marker Therapeutics, Inc.
Interim / Quarterly Report
2026
May 15
Proxy Solicitation & Information Statement
2026
Mar 20
Annual Report
2026
Mar 20
Proxy Solicitation & Information Statement
2026
Mar 20
Annual Report
2026
Mar 18
Regulatory Filings
2026
Feb 9
Director's Dealing
2025
Nov 19
Director's Dealing
2025
Nov 19
Director's Dealing
2025
Nov 19
Major Shareholding Notification
2025
Nov 17